- Patients
- Clinical Research
- Clinical trials
- ProstACT-Global-203
Prostate Cancer
ProstACT-Global-203
A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lutetium (177 Lu) rosopatamab tetraxetan in Combination with Standard of Care Versus Standard of Care Alone in Patients with PSMA Positive Metastatic Castration-Resistant Prostate Cancer Previously after Androgen Receptor Pathway Inhibitor Treatment
Trial overview
Theranostics
Prostate cancer
III
Murdoch (Oncology)
St John of God Murdoch Hospital, 100 Murdoch Drive, Murdoch, WA, 6150, Australia
(08) 9366 1500 receptiononcologymurdoch@genesiscare.comNuclear Medicine Physician
Dr Aviral Singh
MD PGDipCard MSc FAfNM FRACP - Clinical Head of Theranostics and Nuclear Medicine
Murdoch (Oncology)
Disclaimer:
This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.